OncoMatch/Clinical Trials/NCT07298642
Extended-field Proton Therapy for Cervical Cancer
Is NCT07298642 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies non-drug interventions for cervical cancer.
Severe lymphopenia is a common complication of extended-field radiotherapy in cervical cancer, significantly impacting immune function and clinical outcomes. This study aims to evaluate whether proton therapy, with its superior dose distribution, can reduce lymphopenia and improve survival and toxicity profiles compared to photon therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage ≥ IIIC
stage ≥ IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiation therapy
Exception: pelvic or abdominal radiotherapy only
Prior history of pelvic or abdominal radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07298642 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage ≥ IIIC is required.
Is there an age limit?
Yes. Patients must be 85 years or younger and at least 20 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages